Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
MWN-AI** Summary
At the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting, Whitehawk Therapeutics presented compelling real-world analysis confirming MUC16 as a significant therapeutic target for gynecologic cancers, particularly ovarian and endometrial cancers. MUC16, a cell-surface glycoprotein, demonstrated an overexpression in tumors—specifically in high-grade serous ovarian carcinoma (HGSOC) and serous adenocarcinoma subtypes—while remaining limited in normal tissues, highlighting its clinical relevance.
Findings revealed that MUC16 exhibits over two-fold higher expression levels compared to other emerging antibody-drug conjugate (ADC) targets, including NaPi2b and HER2. The stability of MUC16 expression across various disease stages and its consistency in both platinum-sensitive and resistant patients reinforces its suitability for therapy. Dr. Kathleen N. Moore emphasized the need for MUC16-targeted ADCs, like Whitehawk's HWK-016, in both early- and late-line treatment settings.
HWK-016 leverages an advanced design, targeting the membrane-bound version of MUC16, thereby improving therapeutic delivery and efficacy compared to earlier MUC16-targeting approaches that were hindered by the soluble, cleaved form of the glycoprotein. Initial clinical results of HWK-016 from ongoing Phase 1 trials in advanced ovarian and endometrial cancer patients are anticipated in 2027.
Overall, Whitehawk's commitment to refining ADC technology combined with the confirmed bioprofile of MUC16 sets a promising foundation for developing effective treatments for challenging gynecologic cancers. The data presented is another step toward potentially enhancing outcomes for patients with limited treatment options.
MWN-AI** Analysis
Whitehawk Therapeutics (NASDAQ: WHWK) has recently attracted significant attention following its presentation at the SGO 2026 Annual Meeting, where it showcased real-world data highlighting MUC16 as a promising target for antibody-drug conjugate (ADC) therapies in gynecologic cancers. This analysis indicates MUC16's stable and high expression levels across ovarian and endometrial cancers, rendering it a superior choice compared to other targets.
Investors should regard these findings as a strong validation of Whitehawk's ongoing clinical trials, particularly for its lead ADC candidate, HWK-016, currently in Phase 1 development for advanced ovarian and endometrial cancers. The high expression levels of MUC16—averaging 2 to over 100 times more compared to other emerging ADC targets—enhance the therapeutic potential for both early and late-stage treatments.
Moreover, the persistence of MUC16 expression, regardless of disease stage and platinum sensitivity, suggests a wide applicability of HWK-016. This could enable the firm to capture a significant market share in an area with substantial unmet medical needs. The initial clinical data anticipated in early 2027 will be critical for validating these findings and could lead to increased investor interest.
Financially, investors may consider positioning themselves ahead of the data release, as positive results could bolster the company’s market capitalization. However, it is essential to remain vigilant of the inherent risks in clinical development such as potential delays or efficacy concerns, which could impact stock performance.
In summary, Whitehawk Therapeutics is positioned favorably in the oncology sector; a strategic long position could be beneficial as investors await further clinical developments and data releases related to HWK-016.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets
MUC16 is highly and stably expressed in the most aggressive and most common subtypes of endometrial cancer
Findings support Whitehawk's development of MUC16-directed ADC, HWK-016, currently being explored in Phase 1 for advanced ovarian and endometrial cancers
MORRISTOWN, N.J., April 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented three posters from a real-world analysis supporting the therapeutic potential of targeting mucin 16 (MUC16) with a next-generation ADC for the treatment of ovarian and endometrial cancers at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancer, being held April 10-13, 2026, in San Juan, Puerto Rico.
MUC16 is a cell-surface glycoprotein that promotes tumor cell proliferation, metastasis and immune evasion. MUC16 is overexpressed in multiple tumor types with limited expression in normal tissue. A large-scale RNA analysis demonstrated that MUC16 is highly and stably expressed across ovarian cancers and in the most aggressive and most common subtypes of endometrial cancer, including in later-stage disease, supporting its potential as a clinically meaningful ADC target and reinforcing the rationale for clinical development of HWK-016.
"Across both ovarian and endometrial cancers, MUC16 shows a high level of stable expression that is uncommon among many therapeutic targets," said Kathleen N. Moore, MD, Deputy Director and Director of Phase 1 Oncology Trials, The Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center. "The consistency of MUC16 expression across disease stage and platinum sensitivity supports the relevance of a MUC16-targeted ADC in earlier-line settings, as well as for heavily pretreated patients and as part of combination strategies."
Key Findings Include:
MUC16 in Ovarian Cancer
- MUC16 has high, tumor?selective expression, with concordance between MUC16 mRNA expression and MUC16 protein abundance by IHC.
- MUC16 is highly expressed across most histologic subtypes, including the most common subtype, high-grade serous ovarian carcinoma (HGSOC), which accounts for ~70% of cases.
- In HGSOC, MUC16 expression is stable across disease stages, metastatic status and platinum sensitivity, underscoring relevance in early- and late-line treatment settings.
- MUC16 has the highest median expression, ranging from 2- to >100-fold higher than other clinically validated and emerging ADC targets, including NaPi2b, HER2, FR?, TROP2, B7-H4, CDH6 and CLDN6.
MUC16 in Endometrial Cancer
- MUC16 has high, tumor?selective expression, with concordance with MUC16 protein abundance by IHC.
- MUC16 is most highly expressed in serous adenocarcinoma (the most aggressive subtype accounting for ~40% of deaths), followed by endometrioid adenocarcinoma (the most common subtype, accounting for ~90% of cases).
- In serous adenocarcinoma, MUC16 expression is stable across disease stages and metastatic status, and has the highest median expression, 1.4- to 3.7-fold higher than other clinically validated and emerging ADC targets, including NaPi2b, HER2, TROP2, FR? and B7H4.
Earlier MUC16?directed ADCs targeted the cleaved extracellular portion of the protein (CA125), which is shed into circulation, limiting tumor delivery. HWK?016, Whitehawk's investigational, next?generation MUC16?targeted ADC, is designed to overcome this antigen sink effect by selectively targeting the membrane?bound, non?shed portion of MUC16. HWK?016 leverages a stable, cleavable linker to deliver a novel topoisomerase I (TOP1) inhibitor payload. HWK-016 is currently being evaluated in a Phase 1 clinical trial in patients with advanced ovarian and endometrial cancers [NCT07470853]. Initial clinical data are expected in the first half of 2027.
"The real-world data reported at SGO reinforce MUC16 as a 'super expressed' and durable target for gynecological cancers, strengthening the biological rationale for HWK-016," said Margaret Dugan, MD, Chief Medical Officer of Whitehawk Therapeutics. "By combining selective targeting of the membrane?bound, non?shed portion of MUC16 with our differentiated carbon?bridge cystine?repairing linker?payload technology, HWK?016 exemplifies our broader strategy of applying advanced ADC engineering to well?validated tumor biology to potentially generate meaningfully improved outcomes for patients."
Poster Presentation Details:
Title: MUC16 in ovarian cancer: high, stable expression across histologic subtypes, disease stages, and platinum sensitivity status supports antibody-drug conjugate development
Presenter: Ursula A. Matulonis, MD, Dana-Farber Cancer Institute
Date & Time: April 12, 2026, 11:00 AM – 12:00 PM and 4:00 – 4:45 PM
Title: MUC16 as a therapeutic target: advancing antibody-drug conjugates for ovarian cancer treatment
Presenter: David M. O'Malley, MD, The Ohio State University
Date & Time: April 12, 2026, 11:00 AM – 12:00 PM and 4:00 – 4:45 PM
Title: High and stable MUC16 expression in endometrial cancer highlights potential for targeted antibody-drug conjugate development
Presenter: Kathleen N. Moore, MD, University of Nebraska Medical Center
Poster Tour – Group 9: Targeted Tactics and Therapies
Date & Time: April 12, 2026, 11:30 AM – 12:00 PM
The analysis was conducted as part of a previously announced collaboration between Whitehawk and Tempus AI. The posters will be accessible on the Presentations page of the Investors & News section of the Company's website at www.whitehawktx.com.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to expectations regarding the beneficial characteristics, optimized ADC design features, safety, efficacy, therapeutic effects, the size of the potential targeted markets with respect to HWK-016 and anticipated timing of the data release of initial Phase 1 data from clinical trial HWK-016 in the first half of 2027. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties associated with clinical development of HWK-016, including potential delays in the commencement, enrollment and completion of clinical trials; failure to demonstrate the efficacy of clinical studies for HWK-016; and the risk that unforeseen adverse reactions or side effects may occur in the course of testing of HWK-016.
Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov.
All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
SOURCE Whitehawk Therapeutics, Inc.
FAQ**
How does the high and stable expression of MUCacross various cancer stages and subtypes justify the clinical development of HWK-0by Whitehawk Therapeutics Inc. WHWK, particularly in treating advanced ovarian and endometrial cancers?
What specific advantages does the next-generation ADC HWK-016 offer over earlier MUC16-targeted ADCs in terms of targeting tumor cells effectively, as highlighted in Whitehawk Therapeutics Inc. WHWK's recent presentation at SGO 2026?
Can you elaborate on the collaboration between Whitehawk Therapeutics Inc. WHWK and Tempus AI that facilitated the real-world analysis presented at SGO 2026, and how it contributes to the understanding of MUC16 as a therapeutic target?
Given the promising preliminary findings, how does Whitehawk Therapeutics Inc. WHWK plan to address potential risks and uncertainties in the ongoing Phase 1 trial of HWK-016, especially concerning patient safety and efficacy outcomes?
**MWN-AI FAQ is based on asking OpenAI questions about Whitehawk Therapeutics Inc. (NASDAQ: WHWK).
NASDAQ: WHWK
WHWK Trading
30.26% G/L:
$5.015 Last:
4,286,302 Volume:
$4.33 Open:
